A5070554521- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Computational Drug Discovery Methods
- Animal testing and alternatives
- Liver Disease Diagnosis and Treatment
- Pharmacological Effects and Toxicity Studies
- Liver Disease and Transplantation
- HIV-related health complications and treatments
- Drug-Induced Hepatotoxicity and Protection
- Drug Transport and Resistance Mechanisms
- Chemical Synthesis and Analysis
- Click Chemistry and Applications
- Effects and risks of endocrine disrupting chemicals
- Hepatitis C virus research
- HIV Research and Treatment
- Environmental Toxicology and Ecotoxicology
- RNA and protein synthesis mechanisms
- Skin Protection and Aging
Unilever (United Kingdom)
2023-2024
University of Liverpool
2019-2024
Vitenparken
2024
Liverpool John Moores University
2018
Long-acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use pregnancy are limited. Physiologically-based pharmacokinetic (PBPK) modelling was used simulate the dosing regimens explore if C
Abstract A growing number of approaches to “staple” α‐helical peptides into a bioactive conformation using cysteine cross‐linking are emerging. Here, the replacement l ‐cysteine with “cysteine analogues” in combinations different stereochemistry, side chain length and beta‐carbon substitution, is explored examine influence that thiol‐containing residue(s) has on target protein binding affinity well‐explored model system, p53–MDM2/MDMX, which constituted by interaction tumour suppressor p53...
Only a few antiretroviral drugs (ARVs) are recommended for use during the neonatal period and there is need more to be approved increase treatment prophylaxis strategies. Dolutegravir, selective integrase inhibitor, has potential of HIV infection transmission in neonates.To model pharmacokinetics dolutegravir neonates simulate theoretical optimal dosing regimen.The physiologically based pharmacokinetic (PBPK) was built incorporating age-related changes observed neonates. Virtual between 0 28...
The aim of this study was to simulate the drug–drug interaction (DDI) between ritonavir-boosted atazanavir (ATV/r) and rifampicin (RIF) using physiologically based pharmacokinetic (PBPK) modelling, predict suitable dose adjustments for ATV/r treatment people living with HIV (PLWH) co-infected tuberculosis. A whole-body DDI PBPK model designed Simbiology 9.6.0 (MATLAB R2019a) verified against reported clinical data all drugs administered alone concomitantly. contained induction mechanisms RIF...
The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling predict effect liver disease (LD) on pharmacokinetics (PK) dexamethasone (DEX) in treatment COVID-19. A whole-body PBPK model created simulate 100 adult individuals aged 18-60 years. Physiological changes (e.g., plasma protein concentration, size, CP450 expression, hepatic blood flow) and portal vein shunt were incorporated into LD model. implemented by using Child-Pugh (CP) classification system. DEX...
Abstract For many years, a method that allowed systemic toxicity safety assessments to be conducted without generating new animal test data, seemed out of reach. However, several different research groups and regulatory authorities are beginning use variety in silico, chemico vitro techniques inform decisions. To manage this transition animal-free responsibly, it is important ensure the level protection offered by assessment based on approach methodologies (NAMs), at least as high provided...
Developing long-acting products and formulations for infectious diseases is a nontrivial undertaking that frequently classified as high risk low reward by the pharmaceutical industry. The Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP) was founded in 2015 with support of National Institutes Health to encourage, promote, accelerate development such products. Assessment methodology any new proposal brought this group part framework-the LEAP Process-that includes...
Abstract Estimating human exposure in the safety assessment of chemicals is crucial. Physiologically based kinetic (PBK) models which combine information on exposure, physiology, and chemical properties, describing absorption, distribution, metabolism, excretion (ADME) processes a chemical, can be used to calculate internal metrics such as maximum concentration area under concentration-time curve plasma or tissues test next-generation risk assessment. This article demonstrates development...
Aim Long-acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use pregnancy are limited. Physiologically-based pharmacokinetic modelling (PBPK) can predict drug disposition complex populations. Approved dosing regimens were simulated explore if Ctrough was maintained above target concentrations (664 ng/ml 50 respectively). Methods An adult PBPK model developed validated using clinical of non-pregnant adults. This modified by incorporating...
Abstract The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling predict effect liver disease (LD) on pharmacokinetics (PK) dexamethasone (DEX) in treatment COVID-19. A whole-body PBPK model created simulate 100 adult individuals aged 18-60 years. Physiological changes (e.g., plasma protein concentration, size, CP450 expression, hepatic blood flow) and portal vein shunt were incorporated into LD model. implemented by using Child-Pugh (CP) classification...